Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents

Abstract

Radiopharmaceuticals serve as a major part of nuclear medicine contributing to both diagnosis and treatment of several diseases, especially cancers. Currently, most radiopharmaceuticals are based on small molecules with targeting ability. However, some concerns over their stability or non-specific interactions leading to off-target localization are among the major challenges that need to be overcome. Emulsion technology has great potential for the fabrication of carrier systems for radiopharmaceuticals. It can be used to create particles with different compositions, structures, sizes, and surface characteristics from a wide range of generally recognized as safe (GRAS) materials, which allows their functionality to be tuned for specific applications. In particular, it is possible to carry out surface modifications to introduce targeting and stealth properties, as well as to control the particle dimensions to manipulate diffusion and penetration properties. Moreover, emulsion preparation methods are usually simple, economic, robust, and scalable, which makes them suitable for medical applications. In this review, we highlight the potential of emulsion technology in nuclear medicine for developing targeted radionuclide therapies, for use as radiosensitizers, and for application in radiotracer delivery in gamma imaging techniques.

Development and Characterization of Ultrasound-assisted PLGA Nanobubbles for the Triggered Delivery of Pemigatinib by Design of Experiments

“…Patient-specific factors like health state, concurrent medications, and nutrition can also affect pemigatinib absorption and efficacy. [8] Nano formulations, [9] cyclodextrin complexation, [10] salt formation, [11] prodrug approach, [12] co-solvent systems, [13] and others could improve pemigatinib's solubility, stability, and BA. These different formulations may improve pemigatinib's pharmacokinetic (PK) and pharmacodynamic (PD) qualities, making it a better treatment for FGFR-altered cancer patients.…”